While MET amplification is considered to be the main mechanism of MET activation upon resistance to EGFR TKIs in EGFR-mutant NSCLC (13), MET can also be activated by protein overexpression, activating mutations in the kinase domain, exon 14 skipping mutations and gene fusions (12). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.